NO20010021L - Trifunksjonelt reagens for konjugering til et biomolekyl - Google Patents

Trifunksjonelt reagens for konjugering til et biomolekyl

Info

Publication number
NO20010021L
NO20010021L NO20010021A NO20010021A NO20010021L NO 20010021 L NO20010021 L NO 20010021L NO 20010021 A NO20010021 A NO 20010021A NO 20010021 A NO20010021 A NO 20010021A NO 20010021 L NO20010021 L NO 20010021L
Authority
NO
Norway
Prior art keywords
biomolecule
reagent
conjugation
linker
moiety
Prior art date
Application number
NO20010021A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010021D0 (no
Inventor
Scott D Wilbur
Bengt E B Sandberg
Original Assignee
Univ Washington Dept Of Radiat
Mitra Medical Technology Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington Dept Of Radiat, Mitra Medical Technology Ab filed Critical Univ Washington Dept Of Radiat
Publication of NO20010021D0 publication Critical patent/NO20010021D0/no
Publication of NO20010021L publication Critical patent/NO20010021L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20010021A 1998-07-07 2001-01-03 Trifunksjonelt reagens for konjugering til et biomolekyl NO20010021L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE1998/001345 WO2000002050A1 (en) 1998-07-07 1998-07-07 Trifunctional reagent for conjugation to a biomolecule
PCT/SE1999/001241 WO2000002051A1 (en) 1998-07-07 1999-07-07 Trifunctional reagent for conjugation to a biomolecule

Publications (2)

Publication Number Publication Date
NO20010021D0 NO20010021D0 (no) 2001-01-03
NO20010021L true NO20010021L (no) 2001-03-07

Family

ID=20410995

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010021A NO20010021L (no) 1998-07-07 2001-01-03 Trifunksjonelt reagens for konjugering til et biomolekyl

Country Status (8)

Country Link
EP (1) EP1095274B1 (de)
JP (1) JP2002519440A (de)
AT (1) ATE483162T1 (de)
AU (2) AU8366398A (de)
CA (1) CA2336739A1 (de)
DE (1) DE69942802D1 (de)
NO (1) NO20010021L (de)
WO (2) WO2000002050A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
US8951499B2 (en) 1996-02-08 2015-02-10 University Of Washington Trifunctional reagent for conjugation to a biomolecule
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
US7183392B2 (en) 2000-03-27 2007-02-27 Zyomyx, Inc. Site-specific, covalent bioconjugation of proteins
SE0002287D0 (sv) 2000-06-16 2000-06-16 Department Of Radiation Oncolo Biotinderivat
FR2814463B1 (fr) 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
AU2001296124A1 (en) * 2000-10-12 2002-04-22 Mitra Medical Technology Ab Kit for intraperitoneal administration and extracorpeal removal of a drug
US20030031677A1 (en) * 2001-06-25 2003-02-13 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
DE10227599B4 (de) * 2002-06-20 2005-04-28 Proteome Factory Ag Verfahren und Reagenz zur spezifischen Identifizierung und Quantifizierung von einem oder mehreren Proteinen in einer Probe
CA2509103A1 (en) * 2002-12-13 2004-07-01 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
US7438893B2 (en) * 2003-10-02 2008-10-21 Massachusetts General Hospital Polybiotin compounds for magnetic resonance imaging and drug delivery
JP2007512324A (ja) * 2003-11-28 2007-05-17 ミトラ、メディカル、アクチボラグ Erb抗原のターゲッティング
US20110014151A1 (en) * 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
US8106154B2 (en) 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
EP2152312B1 (de) 2007-05-16 2014-12-31 KTB Tumorforschungsgesellschaft mbH Niedrigviskose anthracyclinformulierung
WO2008145609A1 (en) * 2007-05-25 2008-12-04 Novartis Ag Method of making covalent conjugates with his-tagged proteins
FR2918664B1 (fr) * 2007-07-11 2009-10-02 Commissariat Energie Atomique Reactif pseudo peptidique trifonctionnel, ses utilisations et applications.
FI20090100A0 (fi) 2009-03-16 2009-03-16 Wallac Oy Biotinidaasimääritys
CA2825066C (en) 2011-01-31 2019-09-03 Eth Zurich Trifunctional crosslinking reagents comprising a succinimide, a hydrazone and an affinity group
GB201205360D0 (en) * 2012-03-27 2012-05-09 Univ Edinburgh Biotinidase resistant biotinyl compounds
EP3929587A1 (de) * 2020-06-25 2021-12-29 Technische Universität Berlin Vernetzungsreagenz für die biokonjugation zur verwendung bei der proteomik-vernetzung, insbesondere der vernetzungsmassenspektrometrieanalyse

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0310361A3 (de) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Aus drei Verzahnungen bestehendes Konjugat und Verfahren zu seiner Verwendung
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5310916A (en) * 1988-07-19 1994-05-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
EP0596011A1 (de) * 1991-07-19 1994-05-11 Hybritech Incorporated Trifunktionelle verbindungen mit spezifizitaet fuer multi-drug resistente zellen
DE4310141A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidentale trifunktionelle Linker
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1997029114A1 (en) * 1996-02-08 1997-08-14 Board Of Regents Of The University Of Washington Biotin-containing compounds, biotinylation reagents and methods
DE69837706T2 (de) * 1997-07-21 2008-01-10 Active Biotech Ab Zytolyse der geeigneten zielzellen mit superantigen konjugate mittels der induktion von t-zell aktivierung

Also Published As

Publication number Publication date
WO2000002050A1 (en) 2000-01-13
JP2002519440A (ja) 2002-07-02
AU5076799A (en) 2000-01-24
DE69942802D1 (de) 2010-11-11
ATE483162T1 (de) 2010-10-15
AU8366398A (en) 2000-01-24
EP1095274A1 (de) 2001-05-02
WO2000002051A1 (en) 2000-01-13
CA2336739A1 (en) 2000-01-13
NO20010021D0 (no) 2001-01-03
EP1095274B1 (de) 2010-09-29

Similar Documents

Publication Publication Date Title
NO20010021D0 (no) Trifunksjonelt reagens for konjugering til et biomolekyl
ATE407943T1 (de) Zielsuchende verbindungen für verschiedene organe und gewebe
DE50014571D1 (de) Träger-pharmaka-konjugate
NO20005694L (no) Spesifikke bindingsmolekyler for scintigrafi, konjugater som inneholder disse og terapeutiske fremgangsmåter for behandling av angiogenese
CY1110579T1 (el) Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου
PL374875A1 (en) Detecting receptor oligomerization
CA2336564A1 (en) Method for preparing water-soluble cross-linked conjugates
DE69533725D1 (de) Multifunktionelle molekuläre komplexe für den gen-transfer in zellen
WO2003049684A3 (en) Pseudo-antibody constructs
ATE341344T1 (de) Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
MY112488A (en) Process for preparing 1-(2''-deoxy-2'',2''-difluoro-d- ribofuranosyl)-4-aminopyrimidin-one) hydrochloride
WO2008027944A3 (en) Antigenic protein conjugates and process for preparing same
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
KR910005862A (ko) 신규 친수성 유도체, 진단 또는 치료시 그의 응용 그를 함유하는 진단 또는 치료용 키트 및 면역 시약
NO971228D0 (no) Vater
ES2077098T3 (es) Proteinas modificadas con sacaridos, solubles en agua.
WO1998009647A3 (en) Cyanidin compositions and therapeutic and diagnostic uses therefor
FR2735238B1 (fr) Utilisation d'un complexe phycobiliproteine-peptide de liaison en tant que traceur fluorescent
JP2002542820A5 (de)
McIlhinney et al. A simple and rapid method for the production of cholera B-chain coupled to horseradish peroxidase for neuronal tracing
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
DE60031990D1 (de) Synthetische verbindungen mit zwei epitopen für immunoassays
ATE141926T1 (de) Neue cobalamin-säurehydrazide und davon abgeleitete cobalamin-konjugate
AU2001292118A1 (en) Dye-labelled peptide and its diagnostic use
Habuchi et al. Sea urchin egg receptor for sperm: the oligosaccharide chains stabilize sperm binding

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application